<drug type="biotech" created="2005-06-13" updated="2021-01-01">
  <drugbank-id primary="true">DB00103</drugbank-id>
  <drugbank-id>BTD00075</drugbank-id>
  <drugbank-id>BIOD00075</drugbank-id>
  <name>Agalsidase beta</name>
  <description>Agalsidase beta is a recombinant human α-galactosidase A similar to [agalsidase alfa]. While patients generally do not experience a clinically significant difference in outcomes between the two drugs, some patients may experience greater benefit with agalsidase beta.[A220228,A220233] Use of agalsidase beta has decreased in Europe, in favor of agalsidase alfa, after a contamination event in 2009.[A220343]&#13;
&#13;
Agalsidase beta was granted FDA approval on 24 April 2003.[L16383]</description>
  <cas-number/>
  <unii>RZD65TSM9U</unii>
  <state>liquid</state>
  <groups>
    <group>approved</group>
    <group>investigational</group>
  </groups>
  <general-references>
    <articles>
      <article>
        <ref-id>A220228</ref-id>
        <pubmed-id>30775256</pubmed-id>
        <citation>Germain DP, Elliott PM, Falissard B, Fomin VV, Hilz MJ, Jovanovic A, Kantola I, Linhart A, Mignani R, Namdar M, Nowak A, Oliveira JP, Pieroni M, Viana-Baptista M, Wanner C, Spada M: The effect of enzyme replacement therapy on clinical outcomes in male patients with Fabry disease: A systematic literature review by a European panel of experts. Mol Genet Metab Rep. 2019 Feb 6;19:100454. doi: 10.1016/j.ymgmr.2019.100454. eCollection 2019 Jun.</citation>
      </article>
      <article>
        <ref-id>A220233</ref-id>
        <pubmed-id>28510034</pubmed-id>
        <citation>Wilcox WR, Feldt-Rasmussen U, Martins AM, Ortiz A, Lemay RM, Jovanovic A, Germain DP, Varas C, Nicholls K, Weidemann F, Hopkin RJ: Improvement of Fabry Disease-Related Gastrointestinal Symptoms in a Significant Proportion of Female Patients Treated with Agalsidase Beta: Data from the Fabry Registry. JIMD Rep. 2018;38:45-51. doi: 10.1007/8904_2017_28. Epub 2017 May 17.</citation>
      </article>
      <article>
        <ref-id>A220323</ref-id>
        <pubmed-id>22768187</pubmed-id>
        <citation>Prabakaran T, Nielsen R, Satchell SC, Mathieson PW, Feldt-Rasmussen U, Sorensen SS, Christensen EI: Mannose 6-phosphate receptor and sortilin mediated endocytosis of alpha-galactosidase A in kidney endothelial cells. PLoS One. 2012;7(6):e39975. doi: 10.1371/journal.pone.0039975. Epub 2012 Jun 29.</citation>
      </article>
      <article>
        <ref-id>A182009</ref-id>
        <pubmed-id>21698655</pubmed-id>
        <citation>Katsila T, Siskos AP, Tamvakopoulos C: Peptide and protein drugs: the study of their metabolism and catabolism by mass spectrometry. Mass Spectrom Rev. 2012 Jan-Feb;31(1):110-33. doi: 10.1002/mas.20340. Epub 2011 Jun 22.</citation>
      </article>
      <article>
        <ref-id>A220343</ref-id>
        <pubmed-id>25010055</pubmed-id>
        <citation>Pisani A, Riccio E, Sabbatini M: Agalsidase alfa and agalsidase beta in the treatment of Fabry disease: does the dose really matter? Genet Med. 2015 Jan;17(1):21-3. doi: 10.1038/gim.2014.79. Epub 2014 Jul 10.</citation>
      </article>
    </articles>
    <textbooks/>
    <links>
      <link>
        <ref-id>L16383</ref-id>
        <title>FDA Approved Drug Products: Fabrazyme Agalsidase Beta Intravenous Injection</title>
        <url>https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/103979s5303lbl.pdf</url>
      </link>
    </links>
    <attachments/>
  </general-references>
  <synthesis-reference/>
  <indication>Agalsidase beta is indicated in the treatment of Fabry disease.[L16383]</indication>
  <pharmacodynamics>Agalsidase beta is a recombinant human α-galactosidase A used as enzyme replacement therapy in the treatment of Fabry disease.[L16398] It has a long duration of action and a wide therapeutic index.[L16383] Patients should be counselled regarding the risk of infusion related reactions and hypersensitivity.[L16383]</pharmacodynamics>
  <mechanism-of-action>α-galactosidase A is uptaken by cells via the mannose 6 phosphate receptor.[A220323] Agalsidase beta hydrolyzes globotriaosylceramide and other glycosphingolipids that would normally be hydrolyzed by endogenous α-galactosidase A.[L16383] Preventing the accumulation of glycosphingolipids prevents or reduces the severity of manifestations of Fabry disease such as renal failure, cardiomyopathy, or cerebrovascular events.[L16383]</mechanism-of-action>
  <toxicity>Data regarding overdoses of agalsidase beta are not readily available.[L16383] Patients experiencing an overdose of agalsidase beta may experience an increased incidence and severity of adverse effects.[L16383] Overdose can be managed through the use of symptomatic and supportive measures.</toxicity>
  <metabolism>Data regarding the metabolism of agalsidase beta is not readily available.[L16383] However, protein drugs are expected to be degraded by proteases and other catalytic enzymes to smaller peptides and amino acids.[A182009]</metabolism>
  <absorption>A 1 mg/kg dose of agalsidase beta with a mean infusion length of 115 minutes reaches a C&lt;sub&gt;max&lt;/sub&gt; 5.0 ± 1.1 µg/mL with an AUC of 496 ± 137 µg\*min/mL.[L16383]</absorption>
  <half-life>agalsidase beta has a half like of 67 ± 12 min for a 1 mg/kg dose with a mean infusion length of 115 minutes.[L16383]</half-life>
  <protein-binding>Data regarding the protein binding of agalsidase beta is not readily available.[L16383]</protein-binding>
  <route-of-elimination>After nonspecific proteolysis, the amino acids from protein drugs are reused for protein synthesis or further broken down and eliminated by the kidneys.[A182009]</route-of-elimination>
  <volume-of-distribution>A 1 mg/kg dose of agalsidase beta with a mean infusion length of 115 minutes has a V&lt;sub&gt;SS&lt;/sub&gt; of 112 ± 13 mL/kg.[L16383]</volume-of-distribution>
  <clearance>A 1 mg/kg dose of agalsidase beta with a mean infusion length of 115 minutes has a clearance of 2.1 ± 0.7 mL/min/kg.[L16383]</clearance>
  <classification>
    <description/>
    <direct-parent>Peptides</direct-parent>
    <kingdom>Organic Compounds</kingdom>
    <superclass>Organic Acids</superclass>
    <class>Carboxylic Acids and Derivatives</class>
    <subclass>Amino Acids, Peptides, and Analogues</subclass>
  </classification>
  <salts/>
  <synonyms>
    <synonym language="spanish" coder="inn">Agalsidasa beta</synonym>
    <synonym language="english" coder="jan">Agalsidase beta (genetical recombination)</synonym>
  </synonyms>
  <products>
    <product>
      <name>Fabrazyme</name>
      <labeller>Genzyme Europe Bv</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id/>
      <ema-product-code>EMEA/H/C/000370</ema-product-code>
      <ema-ma-number>EU/1/01/188/001</ema-ma-number>
      <started-marketing-on>2001-08-03</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Injection, powder, for solution</dosage-form>
      <strength>35 mg</strength>
      <route>Intravenous</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>EU</country>
      <source>EMA</source>
    </product>
    <product>
      <name>Fabrazyme</name>
      <labeller>Genzyme Europe Bv</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id/>
      <ema-product-code>EMEA/H/C/000370</ema-product-code>
      <ema-ma-number>EU/1/01/188/002</ema-ma-number>
      <started-marketing-on>2001-08-03</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Injection, powder, for solution</dosage-form>
      <strength>35 mg</strength>
      <route>Intravenous</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>EU</country>
      <source>EMA</source>
    </product>
    <product>
      <name>Fabrazyme</name>
      <labeller>Genzyme Europe Bv</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id/>
      <ema-product-code>EMEA/H/C/000370</ema-product-code>
      <ema-ma-number>EU/1/01/188/003</ema-ma-number>
      <started-marketing-on>2001-08-03</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Injection, powder, for solution</dosage-form>
      <strength>35 mg</strength>
      <route>Intravenous</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>EU</country>
      <source>EMA</source>
    </product>
    <product>
      <name>Fabrazyme</name>
      <labeller>Genzyme Europe Bv</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id/>
      <ema-product-code>EMEA/H/C/000370</ema-product-code>
      <ema-ma-number>EU/1/01/188/004</ema-ma-number>
      <started-marketing-on>2001-08-03</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Injection, powder, for solution</dosage-form>
      <strength>5 mg</strength>
      <route>Intravenous</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>EU</country>
      <source>EMA</source>
    </product>
    <product>
      <name>Fabrazyme</name>
      <labeller>Genzyme Europe Bv</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id/>
      <ema-product-code>EMEA/H/C/000370</ema-product-code>
      <ema-ma-number>EU/1/01/188/005</ema-ma-number>
      <started-marketing-on>2001-08-03</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Injection, powder, for solution</dosage-form>
      <strength>5 mg</strength>
      <route>Intravenous</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>EU</country>
      <source>EMA</source>
    </product>
    <product>
      <name>Fabrazyme</name>
      <labeller>Genzyme Europe Bv</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id/>
      <ema-product-code>EMEA/H/C/000370</ema-product-code>
      <ema-ma-number>EU/1/01/188/006</ema-ma-number>
      <started-marketing-on>2001-08-03</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Injection, powder, for solution</dosage-form>
      <strength>5 mg</strength>
      <route>Intravenous</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>EU</country>
      <source>EMA</source>
    </product>
    <product>
      <name>Fabrazyme</name>
      <labeller>Genzyme Corporation</labeller>
      <ndc-id/>
      <ndc-product-code>58468-0041</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2008-12-17</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Injection, powder, lyophilized, for solution</dosage-form>
      <strength>5 mg/1mL</strength>
      <route>Intravenous</route>
      <fda-application-number>BLA103979</fda-application-number>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Fabrazyme</name>
      <labeller>Genzyme Corporation</labeller>
      <ndc-id/>
      <ndc-product-code>58468-0040</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2008-12-17</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Injection, powder, lyophilized, for solution</dosage-form>
      <strength>5 mg/1mL</strength>
      <route>Intravenous</route>
      <fda-application-number>BLA103979</fda-application-number>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Fabrazyme</name>
      <labeller>Sanofi Genzyme, a Division of Sanofi Aventis Canada Inc</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id>02248965</dpd-id>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2004-09-17</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Powder, for solution</dosage-form>
      <strength>5 mg</strength>
      <route>Intravenous</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>Canada</country>
      <source>DPD</source>
    </product>
    <product>
      <name>Fabrazyme</name>
      <labeller>Sanofi Genzyme, a Division of Sanofi Aventis Canada Inc</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id>02248966</dpd-id>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2004-04-08</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Powder, for solution</dosage-form>
      <strength>35 mg</strength>
      <route>Intravenous</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>Canada</country>
      <source>DPD</source>
    </product>
  </products>
  <international-brands/>
  <mixtures>
    <mixture>
      <name>Fabrazyme</name>
      <ingredients>Agalsidase beta</ingredients>
    </mixture>
    <mixture>
      <name>Fabrazyme</name>
      <ingredients>Agalsidase beta</ingredients>
    </mixture>
    <mixture>
      <name>Fabrazyme</name>
      <ingredients>Agalsidase beta</ingredients>
    </mixture>
    <mixture>
      <name>Fabrazyme</name>
      <ingredients>Agalsidase beta</ingredients>
    </mixture>
    <mixture>
      <name>Fabrazyme</name>
      <ingredients>Agalsidase beta</ingredients>
    </mixture>
    <mixture>
      <name>Fabrazyme</name>
      <ingredients>Agalsidase beta</ingredients>
    </mixture>
    <mixture>
      <name>Fabrazyme</name>
      <ingredients>Agalsidase beta</ingredients>
    </mixture>
    <mixture>
      <name>Fabrazyme</name>
      <ingredients>Agalsidase beta</ingredients>
    </mixture>
    <mixture>
      <name>Fabrazyme</name>
      <ingredients>Agalsidase beta</ingredients>
    </mixture>
    <mixture>
      <name>Fabrazyme</name>
      <ingredients>Agalsidase beta</ingredients>
    </mixture>
  </mixtures>
  <packagers>
    <packager>
      <name>Genzyme Inc.</name>
      <url>http://www.genzyme.ca</url>
    </packager>
    <packager>
      <name>Shire Inc.</name>
      <url>http://www.shire.com</url>
    </packager>
  </packagers>
  <manufacturers/>
  <prices>
    <price>
      <description>Fabrazyme 5 mg vial</description>
      <cost currency="USD">771.6</cost>
      <unit>vial</unit>
    </price>
    <price>
      <description>Fabrazyme 35 mg vial</description>
      <cost currency="USD">5403.6</cost>
      <unit>vial</unit>
    </price>
  </prices>
  <categories>
    <category>
      <category>Alimentary Tract and Metabolism</category>
      <mesh-id/>
    </category>
    <category>
      <category>Amino Acids, Peptides, and Proteins</category>
      <mesh-id>D000602</mesh-id>
    </category>
    <category>
      <category>Enzymes</category>
      <mesh-id>D004798</mesh-id>
    </category>
    <category>
      <category>Enzymes and Coenzymes</category>
      <mesh-id>D045762</mesh-id>
    </category>
    <category>
      <category>Galactosidases</category>
      <mesh-id>D005696</mesh-id>
    </category>
    <category>
      <category>Glycoside Hydrolases</category>
      <mesh-id>D006026</mesh-id>
    </category>
    <category>
      <category>Hydrolases</category>
      <mesh-id>D006867</mesh-id>
    </category>
    <category>
      <category>Hydrolytic Lysosomal Neutral Glycosphingolipid-specific Enzyme</category>
      <mesh-id/>
    </category>
    <category>
      <category>Protein Isoforms</category>
      <mesh-id>D020033</mesh-id>
    </category>
    <category>
      <category>Proteins</category>
      <mesh-id>D011506</mesh-id>
    </category>
  </categories>
  <affected-organisms>
    <affected-organism>Humans and other mammals</affected-organism>
  </affected-organisms>
  <dosages>
    <dosage>
      <form>Injection, powder, for solution</form>
      <route>Intravenous</route>
      <strength>35 mg</strength>
    </dosage>
    <dosage>
      <form>Injection, powder, for solution</form>
      <route>Intravenous</route>
      <strength>5 mg</strength>
    </dosage>
    <dosage>
      <form>Injection, powder, for solution</form>
      <route>Intravenous; Parenteral</route>
      <strength>35 MG</strength>
    </dosage>
    <dosage>
      <form>Injection, powder, lyophilized, for solution</form>
      <route>Intravenous</route>
      <strength>5 mg/1mL</strength>
    </dosage>
    <dosage>
      <form>Injection, solution, concentrate</form>
      <route>Intravenous</route>
      <strength>35 mg</strength>
    </dosage>
    <dosage>
      <form>Injection, solution, concentrate</form>
      <route>Intravenous</route>
      <strength>5 mg</strength>
    </dosage>
    <dosage>
      <form>Powder, for solution</form>
      <route>Intravenous</route>
      <strength>35 mg</strength>
    </dosage>
    <dosage>
      <form>Powder, for solution</form>
      <route>Intravenous</route>
      <strength>5 mg</strength>
    </dosage>
    <dosage>
      <form>Injection</form>
      <route/>
      <strength>35 mg</strength>
    </dosage>
    <dosage>
      <form>Injection, powder, lyophilized, for solution</form>
      <route>Intravenous</route>
      <strength>37 mg</strength>
    </dosage>
    <dosage>
      <form>Injection, powder, lyophilized, for solution</form>
      <route>Intravenous</route>
      <strength>5 mg</strength>
    </dosage>
    <dosage>
      <form>Injection, powder, lyophilized, for solution</form>
      <route>Intravenous</route>
      <strength>5.5 mg</strength>
    </dosage>
    <dosage>
      <form>Injection, powder, lyophilized, for solution</form>
      <route>Intravenous</route>
      <strength>35 mg</strength>
    </dosage>
  </dosages>
  <atc-codes>
    <atc-code code="A16AB04">
      <level code="A16AB">Enzymes</level>
      <level code="A16A">OTHER ALIMENTARY TRACT AND METABOLISM PRODUCTS</level>
      <level code="A16">OTHER ALIMENTARY TRACT AND METABOLISM PRODUCTS</level>
      <level code="A">ALIMENTARY TRACT AND METABOLISM</level>
    </atc-code>
  </atc-codes>
  <ahfs-codes>
    <ahfs-code>44:00.00</ahfs-code>
  </ahfs-codes>
  <pdb-entries/>
  <fda-label>//s3-us-west-2.amazonaws.com/drugbank/fda_labels/DB00103.pdf?1265922797</fda-label>
  <patents>
    <patent>
      <number>2265464</number>
      <country>Canada</country>
      <approved>2007-06-26</approved>
      <expires>2017-09-12</expires>
      <pediatric-extension>false</pediatric-extension>
    </patent>
  </patents>
  <food-interactions/>
  <drug-interactions>
    <drug-interaction>
      <drugbank-id>DB00608</drugbank-id>
      <name>Chloroquine</name>
      <description>The therapeutic efficacy of Agalsidase beta can be decreased when used in combination with Chloroquine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00798</drugbank-id>
      <name>Gentamicin</name>
      <description>The therapeutic efficacy of Agalsidase beta can be decreased when used in combination with Gentamicin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01118</drugbank-id>
      <name>Amiodarone</name>
      <description>The therapeutic efficacy of Agalsidase beta can be decreased when used in combination with Amiodarone.</description>
    </drug-interaction>
  </drug-interactions>
  <sequences>
    <sequence format="FASTA">&gt;DB00103 sequence
LDNGLARTPTMGWLHWERFMCNLDCQEEPDSCISEKLFMEMAELMVSEGWKDAGYEYLCI
DDCWMAPQRDSEGRLQADPQRFPHGIRQLANYVHSKGLKLGIYADVGNKTCAGFPGSFGY
YDIDAQTFADWGVDLLKFDGCYCDSLENLADGYKHMSLALNRTGRSIVYSCEWPLYMWPF
QKPNYTEIRQYCNHWRNFADIDDSWKSIKSILDWTSFNQERIVDVAGPGGWNDPDMLVIG
NFGLSWNQQVTQMALWAIMAAPLFMSNDLRHISPQAKALLQDKDVIAINQDPLGKQGYQL
RQGDNFEVWERPLSGLAWAVAMINRQEIGGPRSYTIAVASLGKGVACNPACFITQLLPVK
RKLGFYEWTSRLRSHINPTGTVLLQLENTMQMSLKDLL</sequence>
  </sequences>
  <experimental-properties>
    <property>
      <kind>Molecular Weight</kind>
      <value>45351.6</value>
      <source/>
    </property>
    <property>
      <kind>Molecular Formula</kind>
      <value>C2029H3080N544O587S27</value>
      <source/>
    </property>
  </experimental-properties>
  <external-identifiers>
    <external-identifier>
      <resource>Drugs Product Database (DPD)</resource>
      <identifier>13296</identifier>
    </external-identifier>
    <external-identifier>
      <resource>Drugs Product Database (DPD)</resource>
      <identifier>13300</identifier>
    </external-identifier>
    <external-identifier>
      <resource>PubChem Substance</resource>
      <identifier>46508538</identifier>
    </external-identifier>
    <external-identifier>
      <resource>GenBank</resource>
      <identifier>X14448</identifier>
    </external-identifier>
    <external-identifier>
      <resource>PharmGKB</resource>
      <identifier>PA164746527</identifier>
    </external-identifier>
    <external-identifier>
      <resource>UniProtKB</resource>
      <identifier>P06280</identifier>
    </external-identifier>
    <external-identifier>
      <resource>Wikipedia</resource>
      <identifier>Alpha-galactosidase</identifier>
    </external-identifier>
    <external-identifier>
      <resource>ChEMBL</resource>
      <identifier>CHEMBL2108888</identifier>
    </external-identifier>
    <external-identifier>
      <resource>RxCUI</resource>
      <identifier>338817</identifier>
    </external-identifier>
  </external-identifiers>
  <external-links>
    <external-link>
      <resource>RxList</resource>
      <url>http://www.rxlist.com/cgi/generic3/fabrazyme.htm</url>
    </external-link>
    <external-link>
      <resource>Drugs.com</resource>
      <url>http://www.drugs.com/cdi/agalsidase-beta.html</url>
    </external-link>
  </external-links>
  <pathways/>
  <reactions/>
  <snp-effects/>
  <snp-adverse-drug-reactions/>
  <targets>
    <target position="1">
      <id>BE0004830</id>
      <name>Globotriaosylceramide</name>
      <organism>Humans</organism>
      <actions>
        <action>metabolizer</action>
        <action>ligand</action>
      </actions>
      <references>
        <articles>
          <article>
            <ref-id>A153</ref-id>
            <pubmed-id>19852524</pubmed-id>
            <citation>Schaefer RM, Tylki-Szymanska A, Hilz MJ: Enzyme replacement therapy for Fabry disease: a systematic review of available evidence. Drugs. 2009 Nov 12;69(16):2179-205. doi: 10.2165/11318300-000000000-00000.</citation>
          </article>
          <article>
            <ref-id>A154</ref-id>
            <pubmed-id>20464743</pubmed-id>
            <citation>El Dib RP, Pastores GM: Enzyme replacement therapy for Anderson-Fabry disease. Cochrane Database Syst Rev. 2010 May 12;(5):CD006663. doi: 10.1002/14651858.CD006663.pub2.</citation>
          </article>
          <article>
            <ref-id>A155</ref-id>
            <pubmed-id>19725195</pubmed-id>
            <citation>Lim-Melia ER, Kronn DF: Current enzyme replacement therapy for the treatment of lysosomal storage diseases. Pediatr Ann. 2009 Aug;38(8):448-55.</citation>
          </article>
        </articles>
        <textbooks/>
        <links>
          <link>
            <ref-id>L16383</ref-id>
            <title>FDA Approved Drug Products: Fabrazyme Agalsidase Beta Intravenous Injection</title>
            <url>https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/103979s5303lbl.pdf</url>
          </link>
        </links>
        <attachments/>
      </references>
      <known-action>yes</known-action>
    </target>
  </targets>
  <enzymes/>
  <carriers/>
  <transporters>
    <transporter position="2">
      <id>BE0004494</id>
      <name>Cation-dependent mannose-6-phosphate receptor</name>
      <organism>Humans</organism>
      <actions>
        <action>substrate</action>
      </actions>
      <references>
        <articles>
          <article>
            <ref-id>A220323</ref-id>
            <pubmed-id>22768187</pubmed-id>
            <citation>Prabakaran T, Nielsen R, Satchell SC, Mathieson PW, Feldt-Rasmussen U, Sorensen SS, Christensen EI: Mannose 6-phosphate receptor and sortilin mediated endocytosis of alpha-galactosidase A in kidney endothelial cells. PLoS One. 2012;7(6):e39975. doi: 10.1371/journal.pone.0039975. Epub 2012 Jun 29.</citation>
          </article>
        </articles>
        <textbooks/>
        <links>
          <link>
            <ref-id>L16398</ref-id>
            <title>EMA Summary of Product Characteristics: Replagal Agalsidase Alfa Intravenous Injection</title>
            <url>https://www.ema.europa.eu/en/documents/product-information/replagal-epar-product-information_en.pdf</url>
          </link>
          <link>
            <ref-id>L16383</ref-id>
            <title>FDA Approved Drug Products: Fabrazyme Agalsidase Beta Intravenous Injection</title>
            <url>https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/103979s5303lbl.pdf</url>
          </link>
        </links>
        <attachments/>
      </references>
      <known-action>unknown</known-action>
      <polypeptide id="P20645" source="Swiss-Prot">
        <name>Cation-dependent mannose-6-phosphate receptor</name>
        <general-function>Transmembrane signaling receptor activity</general-function>
        <specific-function>Transport of phosphorylated lysosomal enzymes from the Golgi complex and the cell surface to lysosomes. Lysosomal enzymes bearing phosphomannosyl residues bind specifically to mannose-6-phosphate receptors in the Golgi apparatus and the resulting receptor-ligand complex is transported to an acidic prelyosomal compartment where the low pH mediates the dissociation of the complex.</specific-function>
        <gene-name>M6PR</gene-name>
        <locus/>
        <cellular-location>Lysosome membrane</cellular-location>
        <transmembrane-regions>186-210</transmembrane-regions>
        <signal-regions>1-26</signal-regions>
        <theoretical-pi/>
        <molecular-weight>30993.06</molecular-weight>
        <chromosome-location/>
        <organism ncbi-taxonomy-id="9606">Humans</organism>
        <external-identifiers>
          <external-identifier>
            <resource>HUGO Gene Nomenclature Committee (HGNC)</resource>
            <identifier>HGNC:6752</identifier>
          </external-identifier>
          <external-identifier>
            <resource>UniProtKB</resource>
            <identifier>P20645</identifier>
          </external-identifier>
          <external-identifier>
            <resource>UniProt Accession</resource>
            <identifier>MPRD_HUMAN</identifier>
          </external-identifier>
        </external-identifiers>
        <synonyms>
          <synonym>46 kDa mannose 6-phosphate receptor</synonym>
          <synonym>CD Man-6-P receptor</synonym>
          <synonym>MPR 46</synonym>
          <synonym>MPR46</synonym>
          <synonym>MPRD</synonym>
        </synonyms>
        <amino-acid-sequence format="FASTA">&gt;lcl|BSEQ0013144|Cation-dependent mannose-6-phosphate receptor
MFPFYSCWRTGLLLLLLAVAVRESWQTEEKTCDLVGEKGKESEKELALVKRLKPLFNKSF
ESTVGQGSDTYIYIFRVCREAGNHTSGAGLVQINKSNGKETVVGRLNETHIFNGSNWIML
IYKGGDEYDNHCGKEQRRAVVMISCNRHTLADNFNPVSEERGKVQDCFYLFEMDSSLACS
PEISHLSVGSILLVTFASLVAVYVVGGFLYQRLVVGAKGMEQFPHLAFWQDLGNLVADGC
DFVCRSKPRNVPAAYRGVGDDQLGEESEERDDHLLPM</amino-acid-sequence>
        <gene-sequence format="FASTA"/>
        <pfams>
          <pfam>
            <identifier>PF02157</identifier>
            <name>Man-6-P_recep</name>
          </pfam>
        </pfams>
        <go-classifiers>
          <go-classifier>
            <category>component</category>
            <description>endosome</description>
          </go-classifier>
          <go-classifier>
            <category>component</category>
            <description>integral component of plasma membrane</description>
          </go-classifier>
          <go-classifier>
            <category>component</category>
            <description>late endosome</description>
          </go-classifier>
          <go-classifier>
            <category>component</category>
            <description>lysosomal membrane</description>
          </go-classifier>
          <go-classifier>
            <category>component</category>
            <description>membrane</description>
          </go-classifier>
          <go-classifier>
            <category>component</category>
            <description>perinuclear region of cytoplasm</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>mannose binding</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>mannose transmembrane transporter activity</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>transmembrane signaling receptor activity</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>endosome to lysosome transport</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>receptor-mediated endocytosis</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>signal transduction</description>
          </go-classifier>
        </go-classifiers>
      </polypeptide>
    </transporter>
  </transporters>
</drug>